



photon

**Baseline Disease Characteristics of Patients Who Maintained  
12- and 16-Week Aflibercept 8 mg Dosing Versus Patients with Shortened  
Treatment Intervals Through Week 48 in the Phase 2/3 PHOTON Trial**

**David M. Brown,<sup>1</sup> on behalf of the PHOTON study investigators**

*<sup>1</sup>Retina Consultants of Texas, Houston, TX, USA*